Recombinant Human Ccl28 protein

CCL28 (Chemokine (C-C motif) ligand 28) is a small secreted protein belonging to the CC chemokine family, which plays critical roles in immune regulation and mucosal defense. It is constitutively expressed by epithelial cells in mucosal tissues, including the intestines, respiratory tract, and reproductive organs. CCL28 functions by binding to two receptors, CCR10 and CCR3. guiding the migration of immune cells such as IgA antibody-secreting cells (ASCs), regulatory T cells (Tregs), and eosinophils to mucosal sites. This chemokine is unique in its dual role: it not only mediates immune cell trafficking but also exhibits direct antimicrobial activity against pathogens like bacteria and fungi, enhancing mucosal barrier protection.

Recombinant CCL28 protein is produced using biotechnological methods, often through expression in Escherichia coli or mammalian cell systems, followed by purification to ensure bioactivity. Its recombinant form retains the native protein’s functional properties, enabling researchers to study its immunomodulatory and antimicrobial mechanisms in vitro and in vivo. Studies highlight its involvement in inflammatory diseases, mucosal immunity, and tissue homeostasis. For instance, CCL28 has been implicated in pathologies like inflammatory bowel disease (IBD), allergic inflammation, and cancer, where dysregulated expression correlates with disease progression.

Therapeutic potential of recombinant CCL28 is under exploration, particularly in enhancing mucosal vaccine efficacy or treating infections. Its ability to recruit IgA-producing cells makes it a candidate for improving gut-associated immune responses. However, challenges remain in understanding its context-dependent roles and optimizing delivery strategies for clinical applications. Overall, recombinant CCL28 serves as a vital tool for dissecting mucosal immunity and developing targeted therapies for inflammatory and infectious diseases.